FBI urges ransomware victims to report all infections

The FBI has released a statement urging companies across all industries, healthcare included, to report ransomware attacks to federal law enforcement, helping them get a step up in evaluating just how dire the situation is.

While there are many reasons why some companies avoid reporting the attacks, the FBI says it needs the information in order to gain a better all-around view of the problem.

"Victim reporting provides law enforcement with a greater understanding of the threat, provides justification for ransomware investigations, and contributes relevant information to ongoing ransomware cases,” the FBI said in the release. “Knowing more about victims and their experiences with ransomware will help the FBI to determine who is behind the attacks and how they are identifying or targeting victims.”

The FBI has compiled a list of details that companies can answer to give law enforcement the best opportunity to assess and fix the problem. The list includes filling out data on the date of infection, victim company information, how the infection occurred, ransom amount and overall losses. The FBI also provided a checklist that companies can follow to prevent future ransomware attacks. The list includes backing up data, examining links sent in emails, making sure anti-virus software is up to date and disabling macro scripts.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.